Characterisation of Dynamiker SARS-Cov-2 Neutralization Antibody (Nabs) Lateral Flow Immunoassay (LFA) and Enzyme Immunoassays (Eias) Diasorin Liaison RBD and Abbott Igg Quant in Convalescent Sera of SARS-Cov-2 Patients
DOI:
https://doi.org/10.14738/jbemi.92.12250Abstract
The EIAs (enzyme immunoassays) that react with the SARS-CoV-2 RBD protein and Spike protein such as DiaSorin S1/S2 IgG and Abbott II IgG correlate very well with neutralizing antibodies. LFAs (lateral flow assays) are the fastest and most convenient tests usually performed within 10 – 15 minutes. Several LFAs have been commercialized to detect IgG, IgM antibodies. In this short report we characterised the Dynamiker SARS-CoV-2 neutralising antibodies (Nabs) LFA with EIAs (DiaSorin Liaisons SARS-CoV-2 RBD antibodies and Abbotts IgG spike antibodies) in the sera of Covid-19 convalescent patients (40 – 93 days) post onset of symptoms. The EIAs (DiaSorin Liaisons SARS-CoV-2 RBD antibodies and Abbotts IgG spike antibodies) were detected in the sera of all the Covid-19 convalescent patients (100%), while the LFA Dynamiker SARS-Cov-2 Nabs were found in the sera of 86% of Covid-19 convalescent patients. In addition, the Dynamiker SARS-CoV-2 Nabs lateral flow immunoassay (LFA) had a positive correlation with the DiaSorin Liaison (RBD) and Abbott IgG Quant (Spike) antibody assays.
References
Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, Wolzt M, Wagner OF, Binder CJ, Haslacher H. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays. Microbiol Spectr. 2021 Sep 3;9(1):e0024721. doi: 10.1128/Spectrum.00247-21. Epub 2021 Jun 30. PMID: 34190591; PMCID: PMC8552734.
Grenache DG, Ye C, Bradfute SB. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay. J Appl Lab Med. 2021 Mar 1;6(2):491-495. doi: 10.1093/jalm/jfaa195. PMID: 33098417; PMCID: PMC7665545.
Kim Y, Lee JH, Ko GY, Ryu JH, Jang JH, Bae H, Yoo SH, Choi AR, Jung J, Lee J, Oh EJ. Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test. Diagnostics (Basel). 2021 Aug 19;11(8):1496. doi: 10.3390/diagnostics11081496. PMID: 34441430; PMCID: PMC8393767.
Ragnesola, B., Jin, D., Lamb, C.C. et al. COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. BMC Res Notes 13, 372 (2020). https://doi.org/10.1186/s13104-020-05212-0
Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin Infect Dis. 2020 Dec 17;71(10):2688-2694. doi: 10.1093/cid/ciaa721. PMID: 32497196; PMCID: PMC7314147.
Wang JJ, Zhang N, Richardson SA, Wu JV. Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies. Expert Rev Mol Diagn. 2021 Apr;21(4):363-370. doi: 10.1080/14737159.2021.1913123. Epub 2021 Apr 12. PMID: 33840347; PMCID: PMC8054491.
Temperton NJ, Chan PK, Simmons G, et al. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes. Emerging Infectious Diseases. 2005;11(3):411-416. doi:10.3201/eid1103.040906.
Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, Arinsburg S, Nguyen FT, Mendu DR, Firpo-Betancourt A, Jhang J, Wajnberg A, Krammer F, Cordon-Cardo C, Amler S, Montecalvo M, Hutton B, Taylor J, McDonough KA. Neutralizing Antibody Responses in COVID-19 Convalescent Sera. J Infect Dis. 2021 Jan 4;223(1):47-55. doi: 10.1093/infdis/jiaa673. PMID: 33104179; PMCID: PMC7665673.
Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol. 2021 Nov;6(11):1433-1442. doi: 10.1038/s41564-021-00974-0. Epub 2021 Oct 15. PMID: 34654917; PMCID: PMC8556155.
Patel EU, Bloch EM, Clarke W, Hsieh YH, Boon D, Eby Y, Fernandez RE, Baker OR, Keruly M, Kirby CS, Klock E, Littlefield K, Miller J, Schmidt HA, Sullivan P, Piwowar-Manning E, Shrestha R, Redd AD, Rothman RE, Sullivan D, Shoham S, Casadevall A, Quinn TC, Pekosz A, Tobian AAR, Laeyendecker O. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. J Clin Microbiol. 2021 Jan 21;59(2):e02257-20. doi: 10.1128/JCM.02257-20. PMID: 33139419; PMCID: PMC8111143.
Wu F, Liu M, Wang A, et al. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356–1362. doi:10.1001/jamainternmed.2020.4616
Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, Diamond MS, Gronowski AM, Farnsworth CW. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clin Chem. 2020 Dec 1;66(12):1538-1547. doi: 10.1093/clinchem/hvaa211. PMID: 32894750; PMCID: PMC7499494.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 J. Bolodeoku
This work is licensed under a Creative Commons Attribution 4.0 International License.
